Haemonetics Commences Full-Market Release of Vascade MVP XL Vascular Closure System

August 15, 2024—Haemonetics Corporation announced the full-market release of its Vascade MVP XL mid-bore venous closure system.

The company announced commencement of a limited market release of the device on June 18 after receiving FDA premarket approval in Spring 2024. Since then, it has been used by approximately 80 physicians at more than 30 hospitals across multiple types of procedures.

The Vascade MVP XL is now available to United States hospitals as the newest addition to the company’s Vascade portfolio of vascular closure systems featuring its collapsible disc technology and resorbable collagen patch designed to promote rapid hemostasis.

According to the Haemonetics, the Vascade MVP XL system utilizes 58% more collagen and a larger disc than the Vascade MVP system, providing a robust closure solution for procedures requiring 10- to 12-F sheaths (up to 15-F outer diameter) such as cryoablation or pulsed field ablation procedures and left atrial appendage closure.

Haemonetics’ Vascade portfolio also currently includes the Vascade system for small-bore femoral arterial and venous closure with standard 5- to 6/7-F procedural sheaths, and the Vascade MVP system for mid-bore multi-access femoral venous closure with 6- to 12-F inner diameter procedural sheaths, stated the company.